Milestone Pharmaceuticals Files 8-K: Material Agreement
Ticker: MIST · Form: 8-K · Filed: Mar 18, 2025 · CIK: 1408443
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Milestone Pharma signed a big deal, filing an 8-K on 3/18/25.
AI Summary
On March 18, 2025, Milestone Pharmaceuticals Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Quebec and its principal executive offices are located in Montreal.
Why It Matters
This filing indicates a significant new contract or partnership for Milestone Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks and opportunities, the specifics of which are not detailed in this summary filing.
Key Players & Entities
- Milestone Pharmaceuticals Inc. (company) — Registrant
- March 18, 2025 (date) — Date of earliest event reported
- Montreal (location) — Principal executive offices city
- Quebec (location) — State of incorporation
- (514) 336-0444 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement filed by Milestone Pharmaceuticals?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this summary.
When was this 8-K report filed?
The report was filed on March 18, 2025.
Where are Milestone Pharmaceuticals' principal executive offices located?
Milestone Pharmaceuticals' principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Quebec.
What is Milestone Pharmaceuticals' SIC code?
Milestone Pharmaceuticals' Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the Commission File Number for Milestone Pharmaceuticals?
The Commission File Number for Milestone Pharmaceuticals Inc. is 001-38899.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 regarding Milestone Pharmaceuticals Inc. (MIST).